Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection： a case report and literature analysis

CAO Lei; WANG Feng; LIU Jiyong; CHANG Yingying

doi:10.6039/j.issn.1001-0408.2024.07.17

您当前的位置：

首页 >

文章列表页 >

Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection： a case report and literature analysis

更新时间：2025-09-25

- Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection： a case report and literature analysis
- ZHONGGUO YAOFANG Vol. 35, Issue 7, Pages: 866-871(2024)
- 作者机构：
  
  1.复旦大学附属肿瘤医院药剂科，上海　200032
  2.复旦大学上海医学院肿瘤学系，上海　200032
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.07.17
  CLC： R969.3;R978.7
- Received：15 August 2023，
  
  Revised：2024-03-17，
  
  Accepted：18 March 2024，
  
  Published：15 April 2024
- 稿件说明：
移动端阅览
曹磊,汪丰,刘继勇,等.肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析[J].中国药房,2024,35(07):866-871.

CAO Lei,WANG Feng,LIU Jiyong,et al.Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection： a case report and literature analysis[J].ZHONGGUO YAOFANG,2024,35(07):866-871.
曹磊,汪丰,刘继勇,等.肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析[J].中国药房,2024,35(07):866-871. DOI： 10.6039/j.issn.1001-0408.2024.07.17.

CAO Lei,WANG Feng,LIU Jiyong,et al.Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection： a case report and literature analysis[J].ZHONGGUO YAOFANG,2024,35(07):866-871. DOI： 10.6039/j.issn.1001-0408.2024.07.17.

摘要

富马酸替诺福韦二吡呋酯（TDF）是慢性乙型肝炎的一线治疗用药，随着该药在全球范围内使用的增加，其所致肾损伤的不良事件也引起了业界重视。本文报道了1例61岁既往合并乙型肝炎病毒（HBV）感染的肝癌患者，于2022年3月中旬开始使用TDF，用药2个月后出现肾损伤，其间进行了2个疗程的多纳非尼联合信迪利单抗化疗，同时不规律服用双氯芬酸缓解疼痛。本文使用Naranjo’s评估量表评估出与肾损伤可能相关的药物有TDF和信迪利单抗，可疑相关的药物为多纳非尼和双氯芬酸；结合患者的病情变化、药物致肾损伤的发生率、临床表现、发生时间、发生机制、合并用药及高危因素，最终判断为TDF导致的肾损伤。临床应动态监测肝癌合并HBV感染患者使用TDF后的血肌酐变化情况，必要时可调整抗病毒药物的剂量和选择其他对肾功能影响较小的抗病毒药物，以期为肿瘤患者提供个体化用药建议，降低TDF相关肾损伤发生率。

Abstract

Tenofovir disoproxil fumarate （TDF） is a first-line treatment for chronic hepatitis B. With increasing use worldwide， the adverse events of renal injury caused by this drug have also attracted industry attention. This article reports a 61-year-old patient with liver cancer complicated with hepatitis B virus （HBV） infection. The patient started using TDF in mid-March 2022 and developed kidney injury after 2 months of treatment， during which he received 2 courses of donafenib combined with sintilimab chemotherapy and irregular administration of diclofenac for pain relief. In this paper， Naranjo’s assessment scale was used to evaluate the drugs that may be associated with renal injury， including TDF and sintilimab， and the drugs that are suspected to be associated with renal injury are donafenib and diclofenac. The renal injury caused by TDF can be judged according to the changes in the patient’s condition， the incidence of drug-induced renal injury， clinical manifestations， occurrence time， occurrence mechanism， drug combination， and high-risk factors. The changes of serum creatinine in patients with liver cancer complicated with HBV infection after TDF should be dynamically monitored in the clinic， and the dose of antiviral drugs should be adjusted if necessary and other antiviral drugs with less impact on renal function can be selected， to provide individualized medication recommendations for tumor patients， reduce the incidence of TDF-related renal injury.

关键词

Keywords

references

王亚亚，丁丽，史国琴，等 . 富马酸替诺福韦二吡呋酯致肾损伤的主动监测与危险因素分析 [J ] . 中国药房， 2022 ， 33 （ 22 ）： 2770 - 2774 .

WANG Y Y ， DING L ， SHI G Q ， et al . Active monitoring and risk factor analysis of tenofovir disoproxil fumarate-induced kidney injury [J ] . China Pharm ， 2022 ， 33 （ 22 ）： 2770 - 2774 .

SARIN S K ， KUMAR M ， LAU G K ， et al . Asian-Pacific clinical practice guidelines on the management of hepatitis B：a 2015 update [J ] . Hepatol Int ， 2016 ， 10 （ 1 ）： 1 - 98 .

ZELEKE E D ， ASSEFA D G ， JOSEPH M ， et al . Tenofovir disoproxil fumarate for prevention of mother-to-child transmission of hepatitis B virus：a systematic review and meta-analysis of randomized control trials [J ] . Rev Med Virol ， 2021 ， 31 （ 5 ）： 1 - 16 .

中华医学会肝病学分会，中华医学会感染病学分会，尤红，等 . 慢性乙型肝炎防治指南：2022年版 [J ] . 实用肝脏病杂志， 2023 ， 9 （ 3 ）： I0001 - I0022 .

Chinese Society of Hepatology ， Chinese Medical Association ， Chinese Society of Infectious Diseases ， Chinese Medical Association ， YOU H ， et al . Guidelines for the prevention and treatment of chronic hepatitis B：version 2022 [J ] . J Pract Hepatol ， 2023 ， 9 （ 3 ）： I0001 - I0022 .

NISHIJIMA T ， GATANAGA H ， OKA S . Tenofovir nephrotoxicity among Asians living with HIV：a review of the literature [J ] . Glob Health Med ， 2019 ， 1 （ 2 ）： 88 - 94 .

NARANJO C A ， BUSTO U ， SELLERS E M ， et al . A method for estimating the probability of adverse drug reactions [J ] . Clin Pharmacol Ther ， 1981 ， 30 （ 2 ）： 239 - 245 .

谢炎，黄亚北，蒋文涛 . 免疫检查点抑制剂在肝癌中的应用现状及进展 [J/OL ] . 肝癌电子杂志， 2022 ， 9 （ 1 ）： 65 - 70 （ 2022-04-24 ）[ 2023-03-28 ] . https：//d.wanfangdata.com.cn/periodical/gadzzz202201009 https://d.wanfangdata.com.cn/periodical/gadzzz202201009 . DOI： 10.3969/j.issn.2095-7815.2022.01.009 http://dx.doi.org/10.3969/j.issn.2095-7815.2022.01.009 .

XIE Y ， HUANG Y B ， JIANG W T . Application status and progress of immune checkpoint inhibitors in liver cancer [J/OL ] . Electron J Liver Tumor ， 2022 ， 9 （ 1 ）： 65 - 70 （ 2022-04-24 ）[ 2023-03-28 ] . https：//d.wanfangdata.com.cn/periodical/gadzzz202201009 https://d.wanfangdata.com.cn/periodical/gadzzz202201009 . DOI： 10.3969/j.issn.2095-7815.2022.01.009 http://dx.doi.org/10.3969/j.issn.2095-7815.2022.01.009 .

POSTOW M A ， SIDLOW R ， HELLMANN M D . Immune-related adverse events associated with immune checkpoint blockade [J ] . N Engl J Med ， 2018 ， 378 （ 2 ）： 158 - 168 .

SZNOL M ， FERRUCCI P F ， HOGG D ， et al . Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma [J ] . J Clin Oncol ， 2017 ， 35 （ 34 ）： 3815 - 3822 .

THOMPSON J A ， SCHNEIDER B J ， BRAHMER J ， et al . Management of immunotherapy-related toxicities，version 1. 2022，NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw ， 2022 ， 20 （ 4 ）： 387 - 405 .

CORTAZAR F B ， KIBBELAAR Z A ， GLEZERMAN I G ， et al . Clinical features and outcomes of immune checkpoint inhibitor-associated AKI：a multicenter study [J ] . J Am Soc Nephrol ， 2020 ， 31 （ 2 ）： 435 - 446 .

SHIRALI A C ， PERAZELLA M A ， GETTINGER S . Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients [J ] . Am J Kidney Dis ， 2016 ， 68 （ 2 ）： 287 - 291 .

JHAVERI K D ， WANCHOO R ， SAKHIYA V ， et al . Adverse renal effects of novel molecular oncologic targeted therapies：a narrative review [J ] . Kidney Int Rep ， 2017 ， 2 （ 1 ）： 108 - 123 .

KWIATKOWSKA E ， DOMAŃSKI L ， DZIEDZIEJKO V ， et al . The mechanism of drug nephrotoxicity and the me- thods for preventing kidney damage [J ] . Int J Mol Sci ， 2021 ， 22 （ 11 ）： 6109 .

MORALES-ALVAREZ M C . Nephrotoxicity of antimicrobials and antibiotics [J ] . Adv Chronic Kidney Dis ， 2020 ， 27 （ 1 ）： 31 - 37 .

PERAZELLA M A . Tenofovir-induced kidney disease：an acquired renal tubular mitochondriopathy [J ] . Kidney Int ， 2010 ， 78 （ 11 ）： 1060 - 1063 .

FERNANDEZ-FERNANDEZ B ， MONTOYA-FERRER A ， SANZ A B ， et al . Tenofovir nephrotoxicity：2011 update [J ] . AIDS Res Treat ， 2011 ， 2011 ： 354908 .

李英，陈秋婷，周燕妮，等 . 替诺福韦导致肾损伤高危因素的分析 [J ] . 海军军医大学学报， 2022 ， 43 （ 10 ）： 1201 - 1205 .

LI Y ， CHEN Q T ， ZHOU Y N ， et al . High-risk factors of renal injury induced by tenofovir [J ] . Acad J Nav Med Univ ， 2022 ， 43 （ 10 ）： 1201 - 1205 .

DUIM A R ， ROKX C ， VAN GORP E C ， et al . Proximal tubular dysfunction in an HIV-1 patient with coadministered tenofovir disoproxil-fumarate and ibuprofen [J ] . AIDS ， 2015 ， 29 （ 6 ）： 746 - 748 .

BPHARM S M ， TALBOT A ， TROTTIER B . Acute renal failure in four HIV-infected patients：potential association with tenofovir and nonsteroidal anti-inflammatory drugs [J ] . Can J Infect Dis Med Microbiol ， 2008 ， 19 （ 1 ）： 75 - 76 .

BICKEL M ， KHAYKIN P ， STEPHAN C ， et al . Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration [J ] . HIV Med ， 2013 ， 14 （ 10 ）： 633 - 638 .

EL-SHEIKH A A ， VAN DEN HEUVEL J J ， KOENDERINK J B ， et al . Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein （MRP） 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport [J ] . J Pharmacol Exp Ther ， 2007 ， 320 （ 1 ）： 229 - 235 .

中国临床肿瘤协会指南工作委员会 . 原发性肝癌诊疗指南：2022年版 [M ] . 北京：人民卫生出版社， 2022 ： 113 - 117 .

Guidelines Working Committee of the Chinese Clinical Oncology Association . Diagnosis and treatment guidelines for primary liver cancer：2022 edition [M ] . Beijing ： People’s Health Publishing House ， 2022 ： 113 - 117 .

黄罡，谢青，贺佳，等 . 乙型肝炎病毒相关肝细胞癌抗病毒治疗中国专家共识：2023年版 [J ] . 肝脏， 2023 ， 28 （ 1 ）： 1 - 10 .

HUANG G ， XIE Q ， HE J ， et al . China expert consensus on antiviral therapy for hepatitis B virus-related hepatocellular carcinoma：2023 edition [J ] . Chin Hepatol ， 2023 ， 28 （ 1 ）： 1 - 10 .

HU P ， REN H . Interpretations of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection [J ] . Chin J Hepatol ， 2017 ， 25 （ 6 ）： 415 - 418 .

TERRAULT N A ， LOK A S F ， MCMAHON B J ， et al . Update on prevention，diagnosis，and treatment of chronic hepatitis B：AASLD 2018 hepatitis B guidance [J ] . Hepatology ， 2018 ， 67 （ 4 ）： 1560 - 1599 .

YIP T C F ， WONG V W S ， CHAN H L Y ， et al . Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China [J ] . Gastroenterology ， 2020 ， 158 （ 1 ）： 215 - 225.e6 .

CHOI J ， JO C ， LIM Y S . Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection [J ] . Hepatology ， 2021 ， 73 （ 2 ）： 661 - 673 .

LIANG L Y ， YIP T C ， LAI J C ， et al . Tenofovir alafe- namide is associated with improved alanine aminotransfe- rase and renal safety compared to tenofovir disoproxil fumarate [J ] . J Med Virol ， 2022 ， 94 （ 9 ）： 4440 - 4448 .

LEE I C ， LAN K H ， SU C W ， et al . Efficacy and renal safety of prophylactic tenofovir alafenamide for HBV-infected cancer patients undergoing chemotherapy [J ] . Int J Mol Sci ， 2022 ， 23 （ 19 ）： 11335 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Vedolizumab-associated lung toxicity：a case report and literature analysis

Literature analysis of tislelizumab-induced Stevens-Johnson syndrome and toxic epidermal necrolysis

Literature analysis of clinical features and risk factors of drug-induced hypofibrinogenemia

Safety analysis of fondaparinux in pregnancy based on case report literature

Literature analysis of aplastic anemia/pure red cell aplasia induced by pembrolizumab

Related Author

LIANG Yu

DING Xueli

WU Jun

QUAN Xianghua

ZHAO Jun

ZHANG Chuanzhou

JIANG Man

HAN Rui

Related Institution

Dept. of Gastroenterology， the Affiliated Hospital of Qingdao University

Dept. of Pharmacy， the Affiliated Hospital of Qingdao University

Dept. of Pharmacy， Beijing Tsinghua Changgung Hospital， School of Clinical Medicine， Tsinghua Medicine， Tsinghua University

Quality and Technology Department， No.6 Traditional Chinese Medicine Factory， Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Dept. of Pharmacy， Tsinghua University Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰